Compare WING & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | RYTM |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.8B |
| IPO Year | 2015 | 2017 |
| Metric | WING | RYTM |
|---|---|---|
| Price | $130.70 | $94.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 27 | 14 |
| Target Price | ★ $295.92 | $131.14 |
| AVG Volume (30 Days) | ★ 1.4M | 614.4K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 67.84 | 28.34 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $17.20 | $55.34 |
| Revenue Next Year | $15.86 | $86.06 |
| P/E Ratio | $123.95 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $133.80 | $55.31 |
| 52 Week High | $388.14 | $122.20 |
| Indicator | WING | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 24.84 | 61.47 |
| Support Level | N/A | $82.09 |
| Resistance Level | $267.86 | $100.70 |
| Average True Range (ATR) | 11.62 | 4.04 |
| MACD | -4.49 | 1.46 |
| Stochastic Oscillator | 1.08 | 74.59 |
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.